Inactive Instrument

Other languages Pain Therapeutics, Inc. Nasdaq

Equities

US69562K5065

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam	Mar. 25
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials	Mar. 25
Cassava Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
Cassava Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28
Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer?s Disease Dementia	Feb. 07
Social Buzz: Wallstreetbets Stocks Mostly Up Premarket; Cassava Sciences Poised to Rise, Tesla to Decline	Dec. 13
Cassava Sciences, Inc. Announces Board Appointments	Dec. 07
Cassava Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer?S Disease	Nov. 06
Cassava Sciences Completes Patient Enrollment in Phase 3 Program of Simufilam in Alzheimer's Disease	Nov. 06
Sector Update: Health Care Stocks Retreating Late Afternoon	23-10-25
Sector Update: Health Care	23-10-25
Cassava Sciences Says MRI Data Suggests Simufilam Not Linked to Amyloid-Related Imaging Abnormalities	23-10-25
Cassava Sciences Says MRI Data Suggests Simufilam Not Linked to Amyloid-Related Imaging Abnormalities	23-10-25
Cassava Sciences, Inc. Announces Positive Safety Findings Based on Interim Magnetic Resonance Imaging Brain Data from Alzheimer's Patients	23-10-25
Sector Update: Health Care Stocks Advance in Late Afternoon	23-10-13
Sector Update: Health Care Stocks Rising Friday Afternoon	23-10-13
Cassava Sciences Refutes 'Egregious Misconduct' Allegations in CUNY Report, Calls Findings 'Illegitimate'; Shares Slump	23-10-13
MORNING BRIEFING - USA/Asien	23-10-13
Cassava Sciences Completes Enrollment of 804 Participants for 12-Month Phase 3 Alzheimer's Trial	23-10-02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Pain Therapeutics, Inc. Nasdaq

Equities

US69562K5065

Other languages

Filters